Stay updated on Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details regarding a trial of Nivolumab following partially HLA mismatched BMT in children and adults with sarcoma, focusing on the safety and efficacy of the investigational drug in preventing or delaying relapse or progression of sarcomas.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:40.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as general health condition and prior treatments. Additionally, specific inclusion criteria for the study have been outlined, such as age range and health requirements.
    Difference
    40%
    Check dated 2024-05-22T21:14:26.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:36:49.000Z thumbnail image

Stay in the know with updates to Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page.